| Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer |
|
Medicine details |
|
| Medicine name | dacomitinib (Vizimpro®) |
| Formulation | 15 mg, 30 mg and 45 mg film-coated tablet |
| Reference number | 2264 |
| Indication | As monotherapy for the first line treatment of locally advanced or metastatic non-small cell lung cancer with epidermal growth factor receptor (EGFR) activating mutations |
| Company | Pfizer Ltd |
| BNF chapter | Malignant disease & immunosuppression |
| Submission type | N/A |
| Status | Excluded due to NICE appraisal |
| Date of issue | 21/02/2019 |
| NICE guidance | TA595: Dacomitinib for untreated EGFR mutation-positive non-small-cell lung cancer |